{Reference Type}: Journal Article
{Title}: Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.
{Author}: Frontera JA;Lewin JJ;Rabinstein AA;Aisiku IP;Alexandrov AW;Cook AM;del Zoppo GJ;Kumar MA;Peerschke EI;Stiefel MF;Teitelbaum JS;Wartenberg KE;Zerfoss CL;
{Journal}: Neurocrit Care
{Volume}: 24
{Issue}: 1
{Year}: Feb 2016
{Factor}: 3.532
{DOI}: 10.1007/s12028-015-0222-x
{Abstract}: <B>BACKGROUND: </B>The use of antithrombotic agents, including anticoagulants, antiplatelet agents, and thrombolytics has increased over the last decade and is expected to continue to rise. Although antithrombotic-associated intracranial hemorrhage can be devastating, rapid reversal of coagulopathy may help limit hematoma expansion and improve outcomes.<BR><B>METHODS: </B>The Neurocritical Care Society, in conjunction with the Society of Critical Care Medicine, organized an international, multi-institutional committee with expertise in neurocritical care, neurology, neurosurgery, stroke, hematology, hemato-pathology, emergency medicine, pharmacy, nursing, and guideline development to evaluate the literature and develop an evidence-based practice guideline. Formalized literature searches were conducted, and studies meeting the criteria established by the committee were evaluated.<BR><B>RESULTS: </B>Utilizing the GRADE methodology, the committee developed recommendations for reversal of vitamin K antagonists, direct factor Xa antagonists, direct thrombin inhibitors, unfractionated heparin, low-molecular weight heparin, heparinoids, pentasaccharides, thrombolytics, and antiplatelet agents in the setting of intracranial hemorrhage.<BR><B>CONCLUSIONS: </B>This guideline provides timely, evidence-based reversal strategies to assist practitioners in the care of patients with antithrombotic-associated intracranial hemorrhage.